What are the stages of hypertension and their corresponding treatment options?

Stages of Hypertension and Treatment

Blood pressure is classified into four categories: Normal (<120/<80 mm Hg), Elevated (120-129/<80 mm Hg), Stage 1 Hypertension (130-139/80-89 mm Hg), and Stage 2 Hypertension (≥140/≥90 mm Hg), with treatment intensity escalating based on both BP level and cardiovascular risk. 1, 2

Blood Pressure Classification

The 2017 ACC/AHA guidelines fundamentally changed hypertension staging by lowering diagnostic thresholds compared to JNC 7:

• Normal BP: <120/<80 mm Hg 1, 2
• Elevated BP: 120-129/<80 mm Hg (systolic elevated but diastolic remains normal) 1, 2
• Stage 1 Hypertension: 130-139/80-89 mm Hg 1, 2
• Stage 2 Hypertension: ≥140/≥90 mm Hg 1, 2, 3

When systolic and diastolic readings fall into different categories, always classify the patient by the higher category. 1, 2 Diagnosis requires an average of ≥2 properly measured readings on ≥2 separate occasions, with the patient seated quietly for at least 5 minutes. 1, 2, 3

Treatment by Stage

Normal BP (<120/<80 mm Hg)

• Promote optimal lifestyle habits 1
• Reassess in 1 year 1
• No pharmacological therapy indicated 1

Elevated BP (120-129/<80 mm Hg)

• Initiate nonpharmacological therapy (lifestyle modifications) immediately 1, 2
• Reassess in 3-6 months 1, 2
• No pharmacological therapy unless compelling indications exist 1

The cardiovascular risk gradient begins at this level, with hazard ratios for CHD and stroke between 1.1 and 1.5 compared to normal BP. 1

Stage 1 Hypertension (130-139/80-89 mm Hg)

Treatment depends critically on cardiovascular risk stratification:

For LOW-RISK patients (10-year ASCVD risk <10%):

• Start with lifestyle modifications alone 1, 2
• Reassess in 3-6 months 1, 2
• Add pharmacological therapy ONLY if BP remains ≥140/90 mm Hg after lifestyle intervention trial 1, 2

For HIGH-RISK patients (10-year ASCVD risk ≥10%, diabetes, or CKD):

• Immediately initiate BOTH lifestyle modifications AND a single antihypertensive agent 1, 2
• Reassess in 1 month if on medication 1, 2
• Target BP <130/80 mm Hg 1, 2

This risk-based approach represents a major departure from JNC 7, which used a uniform BP threshold of 140/90 mm Hg for drug initiation. 1 The hazard ratios for CHD and stroke at this BP level are 1.5 to 2.0 compared to normal BP. 1

Stage 2 Hypertension (≥140/≥90 mm Hg)

All patients require immediate pharmacological intervention regardless of cardiovascular risk:

• Immediately initiate BOTH nonpharmacological therapy AND antihypertensive medications 1, 2, 3
• Start with 2 antihypertensive agents of different classes for most patients 1, 3
• Reassess in 1 month after initiating treatment 1, 2, 3
• Target BP <130/80 mm Hg 1, 2, 3

For patients with BP ≥160/100 mm Hg, treat promptly with careful monitoring and aggressive upward dose titration. 1, 3 Check electrolytes and renal function 2-4 weeks after initiating RAS inhibitors or diuretics. 1, 3

First-Line Pharmacological Therapy

Thiazide-type diuretics (chlorthalidone or hydrochlorothiazide), ACE inhibitors/ARBs (lisinopril, losartan), or calcium channel blockers (amlodipine) are first-line agents. 1, 4, 5, 6

For Stage 2 hypertension, typical two-drug combinations include:

• Thiazide diuretic + ACE inhibitor or ARB 1, 6
• Thiazide diuretic + calcium channel blocker 1, 6
• ACE inhibitor/ARB + calcium channel blocker 1, 6

Treatment Targets

• Most adults: <130/80 mm Hg 1, 2, 3
• Adults ≥65 years: Systolic <130 mm Hg 2
• Minimum acceptable control: <150/90 mm Hg 2

A 10 mm Hg reduction in systolic BP decreases cardiovascular events by approximately 20-30%. 6

Critical Caveats

The Stage 1 hypertension category (130-139/80-89 mm Hg) does NOT automatically warrant drug therapy. 1, 2 This is the most common pitfall—many clinicians reflexively prescribe medications at this level. The decision hinges entirely on cardiovascular risk assessment using the ACC/AHA Pooled Cohort Equations, with diabetes and CKD automatically placing patients in the high-risk category. 1

Confirm diagnosis with out-of-office monitoring (home or ambulatory BP) to exclude white coat hypertension before initiating therapy. 3 This prevents overtreatment of patients whose BP is elevated only in clinical settings.

The evidence for treating Stage 1 hypertension in low-risk patients is limited—neither elevated BP nor Stage 1 hypertension was associated with increased cardiovascular mortality in a large Asian cohort, except in those <65 years without prior CVD. 7 Additionally, adults with Stage 1 hypertension do not display the microvascular endothelial dysfunction characteristic of Stage 2 hypertension. 8